Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org

April 2008

 



Wednesday, April 23, 2021
Vidus Ocular, Inc.



Followed by networking, refreshments & wine bar

Vidus Ocular, Inc. is an early-stage company developing the Aquashunt a glaucoma drainage device that can relieve elevated intraocular pressure in patients with or at risk for the development of glaucoma. Glaucoma is a group of chronic disorders, characterized by irreversible damage to the optic nerve. This damage may result from a variety of conditions, but elevated intraocular pressure is believed to be the main causative factor associated with this disease.

In the United States, of the approximately 2.5 million people afflicted with glaucoma only about 1.2 million are actually diagnosed with the disease and monitored by an eye care professional. According to the Glaucoma Foundation and the World Health Organization, glaucoma is the leading cause of bilateral irreversible blindness worldwide and affects some 60 million people, of which just over 20 million have been positively diagnosed and are being treated.

The Aquashunt was designed by M. Bruce Shields, M.D., the Marvin L. Sears Professor and Chairman Emeritus of the Department of Ophthalmology and Visual Science at Yale University School of Medicine. Composed of a biocompatible material that conforms to the shape of the eye, the Aquashunt is quick and easy to implant. It drains aqueous humor from the anterior chamber to the suprachoroidal space a potential space that exists between the sclera and choroid layers of the eye. In a normal healthy eye this space handles approximately 20% of the aqueous fluid outflow. Published studies have demonstrated that this drainage pathway is capable of handling a greater volume of outflow and can provide a clinically meaningful and durable reduction of IOP. 

Upon successful completion of on-going in vitro and in vivo studies, Vidus will commence pilot human trials with the Aquashunt. The latter are expected to begin in the second half of 2008. 

The Company has one issued patent licensed from Yale University and three patent applications. Funding to date has been provided by the company's founders and individual investors.

Speakers

Ben R. Bronstein, M.D.

Co-Founder, President, and Chief Operating Officer, Vidus Ocular, Inc.

M. Bruce Shields, M.D.

Marvin L. Sears Professor and Chairman Emeritus of the Department of Ophthalmology and Visual Science at Yale University School of Medicine; Co-Founder and Chief Scientific and Medical Officer, Vidus Ocular, Inc.

Wednesday, April 23, 2021
3:30 P.M. Registration
4:00 P.M. Seminar
5:00 P.M. Networking, Refreshments & Wine Bar

Location
The Anlyan Center auditorium, Yale Medical School.

Directions & Parking:
http://info.med.yale.edu/maps/cab.html

RSVP
Registration is free, but please RSVP in advance. E-mail to biohaven@yale.edu or call the Yale OCR main number: 203-785-6209.

Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers.
 

 

Also sponsored by Elm Street Ventures.


Presented by CURE and the Yale Office of Cooperative Research.


Additional support from the Yale Entrepreneurial Society and the Yale Biotechnology & Pharmaceutical Society.


 

 
 
Copyright 2008 Connecticut United for Research Excellence. All rights reserved.
Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org
Newsletter developed and edited by
HarveyMalis Communications LLC, Guilford, Conn.